Codex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
Rhea-AI Summary
Codex DNA, Inc. (Nasdaq: DNAY) will release its Q2 2021 financial results on August 10, 2021. The company will host a conference call that same day at 2:00 PM PT to discuss the results and corporate highlights. Interested parties can access the live audio webcast via the company’s website. Codex DNA specializes in automated synthetic biology systems, providing solutions for rapid and accurate DNA and RNA synthesis. Their BioXp™ system enables significant reductions in synthesis time for various applications, including precision medicine and therapeutic development.
Positive
- Codex DNA's BioXp™ system allows for rapid and accurate DNA/RNA synthesis, reducing time from weeks to days.
- The upcoming financial results announcement could provide insights into the company's performance and future outlook.
Negative
- None.
News Market Reaction – DNAY
In the trading session that priced this news, DNAY gained 2.13%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021. Company management will host a conference call on Tuesday, August 10, 2021, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-8880 (international) and referring to conference ID 9909727. Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Codex DNA’s website for 30 days.
About Codex DNA
Codex DNA is empowering scientists with the ability to address many of humanity’s greatest challenges through synthetic biology. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm to create novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.
Contact:
Jennifer McNealey
Chief Financial Officer
ir@codexdna.com